• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Recombinant vesicular stomatitis virus vaccine elicits anti-Ebola seroconversion

byDavid Arsanious
January 26, 2017
in Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. By day 28, all recipients of a recombinant vesicular stomatitis virus (rVSV) vaccine, at each of the three doses tested, demonstrated seroconversion against an Ebola virus glycoprotein.

2. Anti-Ebola glycoprotein titers were higher in patients who received a 20 million or 100 million plaque forming unit (PFU) dose than in patients who received the 3 million PFU dose.

Evidence Rating Level: 2 (Good)       

Study Rundown: The Ebola virus outbreak of 2014 has prompted renewed interest in development of a vaccine that could be used for pre-exposure prophyaxis. This study tested the use of a rVSV live attenuated recombinant virus vaccine that was genetically engineered to replace the VSV glycoprotein with that of the Zaire strain of Ebola virus (ZEBOV). The results of two placebo-controlled, dose-escalation trials of the rVSV-ZEBOV are reported by this paper.

A total of 78 healthy adults, 39 at each site, were enrolled into groups of 13. In each group, 3 participants were randomly assigned to receive placebo and 10 were assigned to receive 3 million, 20 million, or 100 million PFU of the rVSV-ZEBOV vaccine. All the vaccinated volunteers had detectable vaccine viremia at the first visit after vaccination, but viremia was undetectable by day 14 in all vaccines tested at that time point. 80% of volunteers who received 3 million PFU, 95% of volunteers who received 20 million PFU, and 90% of volunteers who received 100 million PFU had undergone seroconversion by day 14. 100% of vaccinated volunteers underwent seroconversion by day 28, as assessed by ELISA against the ZEBOV glycoprotein.

These findings indicate that the rVSV-ZEBOV vaccine may be a promising agent for Ebola virus pre-exposure prophylaxis, as it elicited an antibody response by a single dose. The similarity between the 20 million PFU dose and 100 million PFU dose support the selection of 20 million PFU as the appropriate dose for further clinical trials. These results are strengthened by the two-center, placebo-controlled, dose-escalation design of the study, but may be limited by underpowering that limits its ability to detect differences in the incidence of adverse events between groups.

Click to read the study, published today in NEJM

RELATED REPORTS

2 Minute Medicine Rewind October 16, 2017

2 Minute Medicine Rewind October 17, 2016

Modified vaccinia Ankara booster increases immunogenic response in Ebola Virus disease

Relevant Reading: Ebola virus vaccines: an overview of current approaches

In-Depth [prospective cohort]: This was a phase 1, double-blind, placebo-controlled, dose-escalation trial of rVSV-ZEBOV vaccine. On day 14, the groups that received a dose of 20 million PFU or 100 million PFU had higher geometric titers against the ZEBOV glycoprotein than the group that received a dose of 3 million PFU (857 and 888 vs 283; p = 0.008 and p = 0.02, respectively) and this was also seen on day 28 (4079 and 4079 vs 1300; p = 0.001 and p < 0.001, respectively). There was no significant difference in the mean titer between the group that received a dose of 20 million PFU and the group that received a dose of 100 million PFU.

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ebola
Previous Post

Patient-physician language concordance linked to improved glycemic control

Next Post

No difference between therapeutic hypo- and normo-thermia with in-hospital cardiac arrest in children

RelatedReports

Concomitant HPV vaccine administration equivalent to staggered schedule
Weekly Rewinds

2 Minute Medicine Rewind October 16, 2017

October 25, 2017
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Weekly Rewinds

2 Minute Medicine Rewind October 17, 2016

October 24, 2016
2 Minute Medicine Rewind November 23 – November 30, 2014
Infectious Disease

Modified vaccinia Ankara booster increases immunogenic response in Ebola Virus disease

May 8, 2016
Ebola outbreak projected to exceed 20,000 cases by November
Infectious Disease

Recombinant vesicular stomatitis virus Ebola vaccine demonstrates immunogenicity

May 6, 2016
Next Post
AAP addresses neonatal pain prevention

No difference between therapeutic hypo- and normo-thermia with in-hospital cardiac arrest in children

Molecular testing for Clostridium difficile may not predict disease activity

Bezlotoxumab associated with lower recurrence of C. difficile infection: The MODIFY I and II trials

AAP recommends disaster preparedness measures for children

Swedish study shows better glycemic control with continuous glucose monitoring

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Same appointment mammogram results may result in less stress for patients being screened for breast cancer
  • Increased use of pediatric CT poses significant oncogenic risk [Classics Series]
  • Pediatric asthma morbidity is associated with geographic location and social determinants of health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.